Gene therapy and nasopharyngeal carcinoma

Rhinology

Volumn 50, Issue 2, 2012, Pages 115-121

  Hughes, Jonathan ^a,b   Alusi, Ghassan ^a,b   Wang, Yaohe ^a,c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

^c ZHENGZHOU UNIVERSITY   (China)

Author keywords

Gene therapy; Head and neck cancer; Nasopharyngeal carcinoma

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53;

ADENOVIRUS; ANIMAL; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; GENETICS; HEAD AND NECK TUMOR; HUMAN; METHODOLOGY; NASOPHARYNX CARCINOMA; NASOPHARYNX TUMOR; REVIEW;

ADENOVIRIDAE; ANIMALS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEAD AND NECK NEOPLASMS; HUMANS; NASOPHARYNGEAL NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863825880     PISSN: 03000729     EISSN: None     Source Type: Journal    
DOI: 10.4193/rhin11.239     Document Type: Review

References (77)

1. Parkin DM. Cancer incidence in five continents. Lyon: International Agency for Research on Cancer, 2002.
2. Nielsen NH, Mikkelsen F, Hansen JP. Nasopharyngeal cancer in Greenland. The incidence in an Arctic Eskimo population. Acta Pathol Microbiol Scand A. 1977; 85: 850-858.
3. Fandi A, Altun M, Azli N, Armand JP, Cvitkovic E. Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol. 1994; 21: 382-397.
4. Buell P. The effect of migration on the risk of nasopharyngeal cancer among Chinese. Cancer Res. 1974; 34: 1189-1191.
5. Simons MJE, Shanmugaratnam KE. The biology of nasopharyngeal carcinoma. Geneva: International Union Against Cancer, 1982.
6. Shanmugaratnam K, Sobin LH, WHO Collaborating Centre for the Histological Classification of Upper Respiratory Tract Tumours. Histological typing of upper respiratory tract tumours. Geneva: World Health Organization, 1978.
7. Micheau C, Rilke F, Pilotti S. Proposal for a new histopathological classification of the carcinomas of the nasopharynx. Tumori. 1978; 64: 513-518.
8. Chan AT. Head and neck cancer: treatment of nasopharyngeal cancer. Ann Oncol 2005; 16 Suppl 2: ii265-268.
9. The Gde. Nasopharyngeal Carcinoma: etiology and control. Lyon: International agency for research on Cancer, 1978.
10. Lee AW, Poon YF, Foo Wet al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys. 1992; 23: 261-270.
11. Kwong DL, Pow EH, Sham JS, et al. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function. Cancer. 2004; 101: 1584-1593.
12. McMillan AS, Pow EH, Kwong DL, et al. Preservation of quality of life after intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: results of a prospective longitudinal study. Head Neck. 2006; 28: 712-722.
13. Huncharek M, Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol. 2002; 25: 219-223.
14. Ma J, Mai HQ, Hong MH, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001; 19: 1350-1357.
15. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. Int J Radiat Oncol Biol Phys. 1996; 35: 463-469.
16. Our inheritance, our future: the Department of Health's White Paper on genetics. London: NHS Confederation, 2003.
17. Lehrman S. Virus treatment questioned after gene therapy death. Nature. 1999; 401: 517-518.
18. Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science to clinical application. J Pathol. 2006; 208: 299-318.
19. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-674.
20. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007--an update. J Gene Med. 2007; 9: 833-842.
21. Vile RG, Russell SJ, Lemoine NR. Cancer gene therapy: hard lessons and new courses. Gene Ther. 2000; 7: 2-8.
22. Shiraishi K, Kato S, Han SY, et al. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem. 2004; 279: 348-355.
23. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther. 2005; 16: 1016-1027.
24. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci U S A. 1992; 89: 33-37.
25. Lin X, Huang H, Li S, et al. A phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors. Cancer Biol Ther. 2007; 6: 648-653.
26. Yamamura M, Modlin RL, Ohmen JD, Moy RL. Local expression of antiinflammatory cytokines in cancer. J Clin Invest. 1993; 91: 1005-1010.
27. Lei N, Shen FB, Chang JH, et al. An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors. Cancer Gene Ther. 2009; 16: 33-43.
28. Kaufman HL, Rao JB, Irvine KR, Bronte V, Rosenberg SA, Restifo NP. Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. J Immunother. 1999; 22: 489-496.
29. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer. 2009; 9: 64-71.
30. Kaneda Y, Tabata Y. Non-viral vectors for cancer therapy. Cancer Sci. 2006; 97: 348-354.
31. Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. 2005; 12: 141-161.
32. Shirakawa T. The current status of adenovirus-based cancer gene therapy. Mol Cells. 2008; 25: 462-466.
33. Volpers C, Kochanek S. Adenoviral vectors for gene transfer and therapy. J Gene Med. 2004; 6 Suppl 1: S164-171.
34. Vattemi E, Claudio PP. Adenoviral gene therapy in head and neck cancer. Drug News Perspect. 2006; 19: 329-337.
35. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003; 80: 148-158.
36. Clayman GL, el-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998; 16: 2221-2232.
37. Clayman GL, Frank DK, Bruso PA, Goepfert H. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res. 1999; 5: 1715-1722.
38. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol. 2001; 19: 289-298.
39. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 2000; 60: 6359-6366.
40. Xia ZJ, Chang JH, Zhang L, et al. [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]. Ai Zheng. 2004; 23: 1666-1670.
41. Raab-Traub N, Flynn K, Pearson G, et al. The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. Int J Cancer. 1987; 39: 25-29.
42. Yates JL, Guan N. Epstein-Barr virus-derived plasmids replicate only once per cell cycle and are not amplified after entry into cells. J Virol. 1991; 65: 483-488.
43. Wang L, Shan L, Lo KW, et al. Inhibition of nasopharyngeal carcinoma growth by RTA-expressing baculovirus vectors containing oriP. J Gene Med. 2008; 10: 1124-1133.
44. Goldsmith K, Bendell L, Frappier L. Identification of EBNA1 amino acid sequences required for the interaction of the functional elements of the Epstein-Barr virus latent origin of DNA replication. J Virol. 1993; 67: 3418-3426.
45. Judde JG, Spangler G, Magrath I, Bhatia K. Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia. Hum Gene Ther. 1996; 7: 647-653.
46. Ragoczy T, Heston L, Miller G. The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J Virol. 1998; 72: 7978-7984.
47. Zuo Y, Wu J, Xu Z, et al. Minicircle-oriP-IFNgamma: a novel targeted gene therapeutic system for EBV positive human nasopharyngeal carcinoma. PLoS One. 2011; 6: e19407.
48. Li JH, Chia M, Shi W, et al. Tumor-targeted gene therapy for nasopharyngeal carcinoma. Cancer Res. 2002; 62: 171-178.
49. Wang Y, Xue SA, Hallden G, et al. Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors. Cancer Res. 2005; 65: 1523-1531.
50. Yip KW, Li A, Li JH, et al. Potential utility of BimS as a novel apoptotic therapeutic molecule. Mol Ther. 2004; 10: 533-544.
51. Tsai ST, Fang SY, Jin YT, Su IJ, Yang BC. Analysis of the expression of Fas-L in nasopharyngeal carcinoma tissues. Oral Oncol. 1999; 35: 421-424.
52. Gasco M, Crook T. The p53 network in head and neck cancer. Oral Oncol. 2003; 39: 222-231.
53. Sheu LF, Chen A, Tseng HH, et al. Assessment of p53 expression in nasopharyngeal carcinoma. Hum Pathol. 1995; 26: 380-386.
54. Murono S, Yoshizaki T, Park CS, Furukawa M. Association of Epstein-Barr virus infection with p53 protein accumulation but not bcl-2 protein in nasopharyngeal carcinoma. Histopathology. 1999; 34: 432-438.
55. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 1998; 92: 725-734.
56. Crook T, Nicholls JM, Brooks L, O'Nions J, Allday MJ. High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene. 2000; 19: 3439-3444.
57. Li JH, Li P, Klamut H, Liu FF. Cytotoxic effects of Ad5CMV-p53 expression in two human nasopharyngeal carcinoma cell lines. Clin Cancer Res. 1997; 3: 507-514.
58. Zeng Y, Prabhu N, Meng R, Eldeiry W. Adenovirus-mediated p53 gene therapy in nasopharyngeal cancer. Int J Oncol. 1997; 11: 221-226.
59. Li JH, Huang D, Sun BF, et al. Efficacy of ionizing radiation combined with adenoviral p53 therapy in EBV-positive nasopharyngeal carcinoma. Int J Cancer. 2000; 87: 606-610.
60. Li JH, Lax SA, Kim J, Klamut H, Liu FF. The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1999; 43: 607-616.
61. Weinrib L, Li JH, Donovan J, Huang D, Liu FF. Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and-negative nasopharyngeal carcinoma. Cancer Gene Ther. 2001; 8: 352-360.
62. Chen W, Lee Y, Wang H, et al. Suppression of human nasopharyngeal carcinoma cell growth in nude mice by the wild-type p53 gene. J Cancer Res Clin Oncol. 1992; 119: 46-48.
63. Lax SA, Chia MC, Busson P, Klamut HJ, Liu FF. Adenovirus-p53 gene therapy in human nasopharyngeal carcinoma xenografts. Radiother Oncol. 2001; 61: 309-312.
64. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707.
65. Serrano M. The tumor suppressor protein p16INK4a. Exp Cell Res. 1997; 237: 7-13.
66. Makitie AA, MacMillan C, Ho J, et al. Loss of p16 expression has prognostic significance in human nasopharyngeal carcinoma. Clin Cancer Res. 2003; 9: 2177-2184.
67. Hwang CF, Cho CL, Huang CC, et al. Loss of cyclin D1 and p16 expression correlates with local recurrence in nasopharyngeal car cinoma following radiotherapy. Ann Oncol. 2002; 13: 1246-1251.
68. Lo KW, Huang DP. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol. 2002; 12: 451-462.
69. Rocco JW, Li D, Liggett WH, Jr., et al. p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer. Clin Cancer Res. 1998; 4: 1697-1704.
70. Naruse I, Heike Y, Hama S, Mori M, Saijo N. High concentrations of recombinant adenovirus expressing p16 gene induces apoptosis in lung cancer cell lines. Anticancer Res. 1998; 18: 4275-4282.
71. Kobayashi S, Shirasawa H, Sashiyama H, et al. P16INK4a expression adenovirus vector to suppress pancreas cancer cell proliferation. Clin Cancer Res. 1999; 5: 4182-4185.
72. Lee AW, Li JH, Shi W, et al. p16 gene therapy: a potentially efficacious modality for nasopharyngeal carcinoma. Mol Cancer Ther. 2003; 2: 961-969.
73. Wang GL, Lo KW, Tsang KS, et al. Inhibiting tumorigenic potential by restoration of p16 in nasopharyngeal carcinoma. Br J Cancer. 1999; 81: 1122-1126.
74. Shen CX, Wen Z, Qian YH, Mu SF, Guan XF. Targeted gene therapy of nasopharyngeal cancer in vitro and in vivo by enhanced thymidine kinase expression driven by human TERT promoter and CMV enhancer. J Exp Clin Cancer Res. 2010; 29:94.
75. Han JB, Tao ZZ, Chen SM, Kong YG, Xiao BK. Adenovirus-mediated transfer of tris-shRNAs induced apoptosis of nasopharyngeal carcinoma cell in vitro and in vivo. Cancer Lett. 2011; 309: 162-169.
76. Pan JJ, Zhang SW, Chen CB, et al. Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. J Clin Oncol. 2009; 27: 799-804.
77. O'Shea CC, Johnson L, Bagus B, et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 2004; 6: 611-623.